811788-85-9

Upstream product

• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 100-39-0 benzyl bromide 
• 157665-51-5 3-fluoro-4-nitrobenzoyl chloride 
• 100-51-6 benzyl alcohol 

Downstream Products

• 1311569-03-5 benzyl 3-({4-[bis(tert-butoxycarbonyl)amino]-2-methylbutan-2-yl}amino)-4-nitrobenzoate 
• 1311569-04-6 benzyl 4-amino-3-({4-[bis(tert-butoxycarbonyl)amino]-2-methylbutan-2-yl}amino)benzoate 
• 1311569-05-7 C₃₂H₄₁N₃O₈ 
• 1311569-06-8 benzyl 5,5-dimethyl-1-oxo-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]benzimidazole-8-carboxylate 
• 1311569-02-4 benzyl 3-[(4-hydroxy-2-methylbutan-2-yl)amino]-4-nitrobenzoate 
• 1346567-62-1 C₂₀H₁₅NO₅ 
• 1346564-56-4 C₂₄H₁₉F₂N₅O₅ 
• 1346564-59-7 C₃₁H₂₅F₂N₅O₅ 
• 1346567-63-2 C₂₀H₁₇NO₃ 
• 1346567-64-3 C₂₃H₂₃NO₃ 
• 811788-86-0 benzyl 4-amino-3-fluorobenzoate 

Relevant academic research and scientific papers

Linker Variation and Structure-Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors

The molecular determinants for the activities of the reported benzoic acid (SH4-54), salicylic acid (BP-1-102), and benzohydroxamic acid (SH5-07)-based STAT3 inhibitors were investigated to design optimized analogues. All three leads are based on an N-met

2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS

The present disclosure provides pharmaceutical compositions comprising 2-arylsulfonamido-N-arylacetamide derivatized Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use.

HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE

Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS

The invention relates to compounds of formula (I), and/or pharmaceutically acceptable derivative thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES

The invention relates to compounds of formula (I) wherein: R1 represents a group selected from: formula (II) each ring of which optionally contains a further heteroatom N, Z represents an optional substituent halogen, alk represents alkylene or alkenylene, T represents S, O or NH; R2 represents -C1-6alkyl, -C1-3alkylCN, -C0-3alkylRc, -C1-3alkylRf, -C2-3alkylNRaRb, -C2-3alkylOC1-6alkyl, -C2-3alkylOC1-3alkylCONRaRb, with the proviso that R2 does not represent C2-3alkylmorpholino; X represents phenyl or a 5- or 6- membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C1-4alkyl, -C2-4alkenyl, -CN, -CF3, -NRaRb, -C0-4alkylORe, -C(O)Rd and -C(O)NRaRb; Y represents a substituent selected from hydrogen, halogen, -C1-4alkyl, -C2-4alkenyl, -NRaRb, -NO2, -C(O)NRaRb, -N(C1-4alkyl)(CHO), -NHCOC1-4alkyl, -NHSO2Rd, -C0-4alkylORe, -C(O)Rd, -S(O)nRd, or -S(O)2NRaRb; The other substituents are as defined in claim 1.